Build on the technological strengths of Just.
We are developing a drug product portfolio that leverages the strengths of Just’s technology platform against significant health needs. The current product focus can be divided into two broad categories.
Our current biosimilar products will demonstrate Just’s strong biologics expertise and ability to achieve the highest level of similarity for critical quality attributes. Just plans to develop high quality and low cost biotherapeutics for a global market and will select future biosimilar projects in collaboration with a partner.
Novel and Repositioned Biologics
Our Novel Biologics will target therapeutic areas where there is an unmet medical need and greater cost sensitivity to treatment. Using antibodies or antibody-like molecules for treatment in areas such as infectious disease, a fast, efficient and low cost approach to development and manufacture could mean the difference between success or failure. This is where Just will add value.